Expression analysis of SIR2 and SAPs1-4 gene expression in Candida albicans treated with allicin compared tofluconazole

One of the main factors for virulence of fungus such as Candida albicans is the ability to change its morphology from yeast to hyphae. Allicin, one of the volatile sulfur-oil compounds from freshly crushed garlic, has a variety of antifungal activities. In this study, the effect of allicin on growth and hyphae production in C. albicans as compared to fluconazole, an antifungal drug was investigated using survival time in vitro and microscopic image at different time intervals. Additionally, the expression of selected genes involved in hyphae formation and development such as SIR2 and SAP1-4 was evaluated by semi-quantitative RTPCR and relative real time RT-PCR. Allicin was shown to down-regulate the expression of SIR2 (5.54 fold), similar to fluconazole (3.48 fold) at 2x MIC concentrations. Interestingly, allicin had no effect on SAPs1-4 expression, whereas fluconazole was able to suppress SAP4 expression. Our findings showed that allicin was effective in suppressing hyphae development of C. albicans to an extent that is sometimes equal or more than fluconazole. Moreover, allicin and fluconazole seemed to share a common anti-Candida mechanism through inhibition of SIR2 gene, while fluconazole appeared to also exert its fungistatic effect through another pathway that involved SAP4 suppression.

therapeutic efficacy of sulfadoxine/pyrimethamine against plasmodium faldparum in Yemen

The aim of this study was to determine the sensitivities of Plasmodium falciparum clinical isolates to sulfadoxine/pyrimethamine [SP] using in vivo and in vitro methods. In vivo and Mark III in-vitro test techniques according to World Health Organization protocols of antimalarial drug tests were used to determine the SP susceptibility of the P. falciparum isolates from 100 malaria patients of both sexes between the ages of 3.5 and 45 years and living in Tihamah, Yemen. The study was conducted between 19 March and 12 May 2005. In vivo: no therapeutic failure occurred; the clinical outcome matched the parasitological response and all patients were parasite free by day 3 and remained so on days 7, 14 and 28. In vitro: all the P. falciparum isolates developed to schizonts in zero-drug-concentration wells, but were inhibited in 40 nmol/l of SP; the mean effective concentration [EC99] was 67.17 nmol/l. Our findings showed that the SP combination is still effective for the treatment of uncomplicated P. falciparum malaria in Yemen. It is recommended that further studies be carried out to address the importance of dihydropteroate synthetase/dihydrofolate reductase mutations as predictive markers of sulfadoxine/pyrimethamine resistance in Yemen

prevalence and degree of resistance of Plasmodium falciparum to first-line antimalarial drugs: an in vitro study from a malaria endemic region in Yemen

Unpublished studies on antimalarial drug efficacy have found low levels of chloroquine resistance in Yemen. This study was carried out to determine the current prevalence of drug resistance in Plasmodium falciparum in Yemen to the main anti-malarial drugs and to determine the effective concentration[EC] values. The WHO standard protocol was used for the selection of subjects, collection of blood samples, culture techniques, examination of post-culture blood slides and interpretation of results. The in vitro micro-test Mark III was used for assessing susceptibility of P. falciparum isolates. The criteria for blood parasite density was met by 219 P. falciparum malaria patients. Chloroquine resistance was found in 47% of isolated P. falciparum schizonts. Mefloquine resistanfce was found in 5.2%. In addition, the EC50 and EC95 values in blood that inhibited schizont maturation in resistant isolates were higher than the normal therapeutic level of mefloquine. No resistance occurred against quinine or artemisinin, with no growth at hte cut-off level of quinine and inhibition of low concentrations of artemisinin. Our study confirmed the occurrence of chloroquine-resistant P. falciparum and a slow increase in the rate of this resistance; it is likely that resistance will increase further and spread over all the foci of malaria in Yemen. The low rate of mefloquine-resistant P. falciparum, was lower than that reported in Africa or Southeast Asia, but it is the first report of mefloquine resistance in Yemen. Finally, the isolates were sensitive to low-concentrations of quinine and artemisinin

Increasing single and multi-antibiotic resistance in Shigella epecies isolated from shigellosis patients in Sana'a, Yemen

The epidemiology and antibiotic susceptibility of Shigella species changes over time. Updated susceptibility knowledge is necessary for appropriate empirical antibiotic treatment. Thus, this research aimed to study these changes in 2 time periods with an interval of 10 years. Two hundreds and three Shigella strains, isolated from stool samples of diarrheic patients at the Central Health Laboratory in Sana'a, Yemen in 2 time periods [1993 and 2003] with a 10-year interval, were examined for serotyping and drug resistance pattern. Resistance patterns of the strains to 12 commonly used antimicrobial agents and minimum inhibitory concentrations of the antibiotics were tested. Shigella flexneri [60%] was found to be the most common isolate of the total Shigella species, followed by Shigella dysenteriae [28.6%] and Shigella boydii [11.3%]. In Shigella flexneri strains, Shigella flexneri 3 [30.5%] was the most prevalent serotype, followed by Shigella flexneri 6 [17.2%], and Shigella flexneri 1 [12.3%]. All strains were found equally susceptible to cefotaxime, ceftriaxone, ciprofloxacin, and gentamicin, but more than 80% of the strains of 2003 were resistant to tetracycline, co-trimoxazole, and 52% of the same strains were resistant to ampicillin. Resistance to chloramphenicol was found in 61%, cefuroxime in 56.2%, and cephradine, 52% of the strains. Overall, Shigella species showed statistically significant increase in resistance against tetracycline, cephradine, trimethoprim/sulfamethoxazole, nalidixic acid, and aztreonam [p<0.05] over the 10 years period. This indicates decreased efficacy of co-trimoxazole and nalidixic acid for the empirical treatment of shigellosis in Sana'a, Yemen. Almost 55.2% of the strains were resistant to 4 drugs. This is one of the first studies reporting epidemiological pattern of Shigella species in Sana'a, Yemen with regard to serotypes and antibiotic resistance patterns. Based on these antibiotic resistance pattern findings, it is suggested that the commonly in use antibiotics including ampicillin, trimethoprim/sulfamethoxazole, tetracycline, and chloramphenicol should not be used for empirical treatment of shigellosis in Yemen